129735-00-8

Rp-8-Br-cAMPS is an analog of cAMP and an inhibitor of PKA. Rp-8-Br-cAMPS occupies cAMP binding sites on PKA type I regulatory subunits, thereby preventing PKA dissociation and activation. Rp-8-Br-cAMPS can be used in the study of tumors and retrovirus-induced immune deficiency. Rp-8-Br-cAMPS also inhibits insulin secretion[1][2][3].

Cell permeable: yes''Primary Target
PKA 1''Product does not compete with ATP.''Reversible: yes

[1] Raskovalova T, et al. Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells: involvement of protein kinase A isozyme I (PKA I). Immunol Res. 2006;36(1-3):91-9. DOI:10.1385/IR:36:1:91
[2] Yang S, et al. Enhanced cAMP protein kinase A signaling determines improved insulin secretion in a clonal insulin-producing beta-cell line (INS-1 832/13). Mol Endocrinol. 2004 Sep;18(9):2312-20. DOI:10.1210/me.2004-0148
[3] Nayjib B, et al. In vivo administration of a PKA type I inhibitor (Rp-8-Br-cAMPS) restores T-cell responses in retrovirus-infected mice[J]. The Open Immunology Journal, 2008, 1(1).